Selective Analysis of Dopamine Receptor Antagonist LE300 and its N-Methyl Metabolite in Mouse Sera at the Trace Level by HPLC–Fluorescence Detection
- 21 March 2015
- journal article
- research article
- Published by Springer Nature in Chromatographia
- Vol. 78 (9-10) , 655-661
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effectJournal of Chromatography A, 2014
- Anticoagulant Counter Ion Impact on Bioanalytical LC–MS/MS Assay Performance: Additional Validation Required?Bioanalysis, 2011
- Residues at the Indole‐NH of LE300 Modulate Affinities and Selectivities for Dopamine ReceptorsArchiv der Pharmazie, 2010
- Harmonization of strategies for the validation of quantitative analytical proceduresJournal of Pharmaceutical and Biomedical Analysis, 2007
- Dopamine/Serotonin Receptor Ligands. 10: SAR Studies on Azecine-type Dopamine Receptor Ligands by Functional Screening at Human Cloned D1, D2L, and D5 Receptors with a Microplate Reader Based Calcium Assay Lead to a Novel Potent D1/D5 Selective AntagonistJournal of Medicinal Chemistry, 2005
- Dopamine/serotonin receptor ligands. Part VIII[1]:the dopamine receptor antagonist LE300 - modelled and X-ray structure plus further pharmacological characterization, including serotonin receptor binding, biogenic amine transporter testing and in vivo testingsEuropean Journal of Medicinal Chemistry, 2004
- Pharmacological characterization of the benz[ d ]indolo[2,3- g ]azecine LE300, a novel type of a nanomolar dopamine receptor antagonistNaunyn-Schmiedeberg's Archives of Pharmacology, 2002
- Dopamine receptors—physiological understanding to therapeutic intervention potentialPharmacology & Therapeutics, 1999